Why the study?
Does an elevated neutrophil-to-lymphocyte ratio (>3.0) predict adverse cardiovascular events and correlate with inflammation in patients with ischemic heart disease?
Observational (n=338)
No
Does an elevated neutrophil-to-lymphocyte ratio (>3.0) predict adverse cardiovascular events and correlate with inflammation in patients with ischemic heart disease?
Absolute Event Rate: 49.5% vs 87.6%
p-value: p=0.001
An elevated neutrophil-to-lymphocyte ratio (>3.0) is a simple, accessible biomarker that correlates with systemic inflammation and predicts worse 3-year event-free survival in patients with ischemic heart disease.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Strilchuk et al. (2020) conducted an observational in Ischemic heart disease (n=338). Neutrophil-to-lymphocyte ratio (NLR) > 3.0 vs. Neutrophil-to-lymphocyte ratio (NLR) < 3.0 was evaluated on 3-year event-free survival (absence of acute coronary syndrome, stroke, peripheral thrombosis) (p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: